Our results indicate HER2-3 heterodimers measured in blood exosomes can increase or decrease following treatment and our preliminary results indicate that the relationship between this dynamic response and tumour response as assessed by RECIST should be further defined in patients with metastatic colorectal cancer treated with anti-HER therapies. This evidence concerns the gene ERBB2 and neoplasm.